Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734560 · ClinicalTrials.gov registry record · Phase 1
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
A Phase 1 study of Newly Diagnosed MGMT Unmethylated Glioblastoma, sponsored by Darell Bigner.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05734560: Recruiting Phase 1 study of Newly Diagnosed MGMT Unmethylated Glioblastoma, sponsored by Darell Bigner.
NCT05734560 is a Phase 1 study of Newly Diagnosed MGMT Unmethylated Glioblastoma that is actively recruiting participants, run by Darell Bigner. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734560, a Phase 1 study of Newly Diagnosed MGMT Unmethylated Glioblastoma, is actively recruiting participants, sponsored by Darell Bigner.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by later repeated injections of 2141-V11 in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adults newly diagnosed with a type of cancerous brain tumor called glioblastoma. The word "investigational" means the study drugs are still being tested in research studies and are not approved by the U.S. Food and Drug Administration (FDA).
Conditions Studied
Interventions
- DRUG D2C7-IT
- DRUG 2141-V11
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 1 |
What NCT05734560 shows while recruiting
NCT05734560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Newly Diagnosed MGMT Unmethylated Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which D2C7-IT is the first listed.
NCT05734560 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05734560 about?
NCT05734560 is a clinical study titled "D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients". The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by later repeated injec...
What is the current status of trial NCT05734560?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-06. Estimated completion is 2028-10-31.
What conditions does trial NCT05734560 study?
This clinical trial studies the following conditions: Newly Diagnosed MGMT Unmethylated Glioblastoma.
What interventions are being tested in trial NCT05734560?
The interventions under investigation include: D2C7-IT (DRUG), 2141-V11 (DRUG).
Who is sponsoring clinical trial NCT05734560?
This trial is sponsored by Darell Bigner, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734560 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05734560's enrollment target sits among peer trials
50 974th of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI